Finance
Results: 22957-22968 of 39909

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease

NX Group Releases Two New Brand Movies: "NX welcomes cargo-partner" and "Meet NX Group: Connecting the World"






